Mavacamten: A Game Changer For Patients With HCM

from Love Your Heart: A Cleveland Clinic Podcast · host Cleveland Clinic Heart & Vascular Institute

Hypertrophic cardiomyopathy (HCM) causes thickening of the heart muscle, left ventricular stiffness, mitral valve changes and cellular changes. For many years, management of this condition was surgery or alcohol ablation. Mavacamten is the first FDA approved drug to help treat patients with HCM. Drs. Steven Nissen and Milind Desai talk about this novel treatment option and the benefits of being treated by a specialized center.

Episode metadata supplied by the publisher feed · Published Nov 15, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Mavacamten: A Game Changer For Patients With HCM

0:00 10:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Love Your Heart: A Cleveland Clinic Podcast?

This episode is 10 minutes long.

When was this Love Your Heart: A Cleveland Clinic Podcast episode published?

This episode was published on November 15, 2022.

Can I download this Love Your Heart: A Cleveland Clinic Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!